TCM
TTNP

Tradewinds Capital Management’s Titan Pharmaceuticals TTNP Stock Holding History

Tradewinds Capital Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2
Closed – – 709
2020
Q2 		$0 Buy
+2
New +$344 ﹤0.01% 720

Other funds holding TTNP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Tradewinds Capital Management's TTNP Position: Q3 2020 in Review

Tradewinds Capital Management sold out of Titan Pharmaceuticals (TTNP) in Q3 2020, closing a stake of 2 shares.

Tradewinds Capital Management first reported a position in TTNP in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 16 funds tracked by Wall St. Rank hold TTNP as of Q3 2020.

  • Tradewinds Capital Management reported no remaining Titan Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Tradewinds Capital Management sold 2 Titan Pharmaceuticals shares in Q3 2020.
  • Tradewinds Capital Management first reported a position in Titan Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Tradewinds Capital Management's Titan Pharmaceuticals position peaked at $0 in Q2 2020.
  • 16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2020.

Based on Tradewinds Capital Management's 13F filing for Q3 2020, filed 26 Oct 2020.